The Clinical Application Of CIK Combined With DC Cellular Immunotherapy For The Metastatic Breast Cancer

Objective: To observe the efficacy and toxicity of the combination ofchemotherapy with DC-CIK cellular immunotherapy and chemotherapy alonein metastatic breast cancer (MBC) patients, provide a new method for totalmanagement of MBC patients，and obtain a better clinical efficacy.Methods: This study was executed on41patients, all the patients wereafter the operation and the postoperative adjuvant chemotherapy, with thespecific histopathological examination, and proved to be MBC throughultrasonic B，CT，MRI or bone scan. All the patients were randomly separatedinto two groups, chemotherapy group (TA regimen) and combination treatmentgroup (DC-CIK cellular immunotherapy combined with TA regimen). Theresponse rate (RR), disease control rate (DCR), adverse reactions of thechemotherapy and DC-CIK cellular immunotherapy, the variance ofT-Lymphocyte Subsets before and after the treatment, and the quality of lifewere observed in the both groups. The therapeutic evaluation were evaluatedfollowing the RECIST (Response Evaluation Criteria In Solid Tumors), whichis used generally in these years. The chemotherapy adverse reactions weredivided into0～Ⅳ grades according to the WHO criterion. And the datas wereprocessed by the software of SPSS13.0.Results:（1）Among the patients in chemotherapy group, about60.0%patients achieved to RR after the TA chemotherapy, and about75.0%patientsachieved to DCR.(2) Among the patients in combination treatment group,about71.0%patients achieved to RR after the treatment, and about85.7%patients achieved to DCR. Both the RR and the DCR were increased in thecombination treatment group，but this result has no significantly statistical differences（p＞0.05）.(3) The main adverse reactions of the chemotherapygroup were performed as alopecia and leukocytopenia, the occurring rates were80.0%and85.0%respectively. And the main adverse reactions of thecombination group performed the same as the other group, but the occurringrates were76.2%and71.4%， this result has no significantly statisticaldifferences（p＞0.05）. After the DC-CIK cellular immunotherapy, about twopatients in the combination group got a transient fever, and were didn’tdiscover other severe adverse reactions in this group.(4) After the DC-CIKcellular immunotherapy, the T-Lymphocyte Subsets of the patients in thecombination treatment group changed. The results of the CD3~+、CD3~+/CD4~+、CD3~+/CD8~+、CD4~+/CD8~+、CD3-/CD16~+56~+were increased, and CD3~+/CD8~+decreased obviously. And the body immunity was improved，this result hassignificantly statistical differences （p＜0.05）.(5) The patients in thecombination treatment group felt much better in tired fatigue, anepithymia，andsleepless night sweats after the DC-CIK cellular immunotherapy, in comparingof the chemotherapy group. And this result has significantly statisticaldifferences，（p＜0.05）.Conclusions: In comparing of the chemotherapy group, the RR and DCRof the combination treatment group was increased, and the recently curativeeffect was good. Except the transient fever, we didn’t discover other obviousadverse reactions in the combination group. In the combination group, patientswho were after the DC-CIK cellular immunotherapy got the T-Cell Subsetschanged, the immunosuppressive states ameliorated, the body immunityimproved, the quality of life enhanced obviously. All the above clarified thatthe combination of DC-CIK cellular immunotherapy and TA planchemotherapy has a promising prospect in treating metastatic breast cancer.